NCT02712866View on ClinicalTrials.gov

Early Biomarkers in Circulating α 4β7 + T Cells to Predict Response to Vedolizumab in Inflamatory Bowel Disease Patients.

CompletedOBSERVATIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

February 28, 2019

Study Completion Date

February 28, 2019

Conditions
Inflammatory Bowel Disease
Interventions
DRUG

Vedolizumab

Administration of intravenous Vedolizumab in inflammatory bowel disease patients

Trial Locations (1)

08003

Hospital del Mar, Barcelona

All Listed Sponsors
lead

Parc de Salut Mar

OTHER

NCT02712866 - Early Biomarkers in Circulating α 4β7 + T Cells to Predict Response to Vedolizumab in Inflamatory Bowel Disease Patients. | Biotech Hunter | Biotech Hunter